Global Dystonia Drugs Market Size study & Forecast, by Drug Type (Anticonvulsants drugs, Dopaminergic agents, GABAergic agents, Others) by Route of Administration (Oral, Injectable), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Sto

Global Dystonia Drugs Market Size study & Forecast, by Drug Type (Anticonvulsants drugs, Dopaminergic agents, GABAergic agents, Others) by Route of Administration (Oral, Injectable), by Distribution Channel (Hospital Pharmacies, Online Providers, Drug Stores and Retail Pharmacies) and Regional Analysis, 2022-2029

Global Dystonia Drugs Market is valued at approximately USD 806.7 million in 2021 and is anticipated to grow with a healthy growth rate of more than 5.5% over the forecast period 2022-2029. Dystonia may be classified as a movement disorder that is characterized by involuntary muscle contractions that cause slow repetitive motions or abnormal postures. These muscular contractions cause unusual body postures and movements. Different types of dystonia might affect a single muscle, a group of muscles, or the entire body's muscles. It is caused by disorders including birth-related brain injury, certain infections, brain trauma, or different vascular abnormalities such as stroke, arteriovenous, and others. It makes patients' movements unpleasant or might cause tremors. Although dystonia does not have a specific treatment, some drugs can help to ease its symptoms. The expansion of the dystonia drugs market is anticipated to be driven by significant upside in untapped, emerging markets, owing to availability of strengthening healthcare infrastructure, rising unmet health care requirements, and an increase in demand for advanced healthcare facilities. The market is expanding due to a rise in both the incidence of dystonia and the prevalence of other neurological illnesses with symptoms similar to dystonia. The market for drugs for dystonia is also expanding as a result of an increase in R&D activity in both developed and developing nations. Researchers' efforts to develop and invent new medicines for the treatment of various medical diseases have significantly increased. The development of new, highly potent drug molecules is the main area of research at present. Drug development innovations are also being used to provide potent dystonia drug treatments. Thus, a rise in this research is fueling the market for drugs for dystonia.

As per National Organization for Rare Disorders, Inc. (NORD), in 2020 stated that there were 300,000 persons in North America who were affected by different types of dystonia. The prevalence of dystonia is increasing, which raises the need for drugs to treat it and fuels the market share growth of drugs for dystonia. Additionally, the rising investment in the healthcare sector and cohesive government support is anticipated to create a lucrative opportunity for the market. However, the lack of awareness about dystonia stifles market growth throughout the forecast period of 2022-2029.

The key regions considered for the Global Dystonia Drugs Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. North America is the dominating region across the world in terms of market share, owing to the presence of key market players, increasing incidences of dystonia along with the rising prevalence of other neurological conditions causing dystonia. Whereas, Asia Pacific is also anticipated to exhibit the highest growth rate over the forecast period, owing to factors such as rising infrastructure of industries, and increasing disposable incomes, as well as the well-established presence of domestic companies in the region, would create lucrative growth prospects for the Dystonia Drugs market across Asia Pacific region.

Major market player included in this report are:
Pfizer Inc
Novartis AG
Sanofi
Merck & Co Inc
Aspan Holdings
China Shineway Pharmaceutical Group Limited
Boston Scientific Corporation
Ipsen Pharma
Revance therapeutics Inc
Merz Pharma

Recent Developments in the Market:
In June 2022, Amneal Pharmaceuticals, Inc. announced the launch of LYVISPAH, a baclofen oral granules specialized product approved by the U.S. Food and Drug Administration for diagnosis of spasticity related to multiple sclerosis and some other spinal cord disorders.

Global Dystonia Drugs Market Report Scope:
Historical Data 2019-2020-2021
Base Year for Estimation 2021
Forecast period 2022-2029
Report Coverage Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered Drug Type, Route of Administration, Distribution Channel, Region
Regional Scope North America; Europe; Asia Pacific; Latin America; Rest of the World

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players.

The detailed segments and sub-segment of the market are explained below:

By Drug Type:
Anticonvulsants drugs
Dopaminergic agents
GABAergic agents
Others
By Route of Administration:
Oral
Injectable
By Distribution Channel:
Hospital Pharmacies
Online Providers
Drug Stores and Retail Pharmacies
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
RoLA
Rest of the World

Companies Mentioned

Pfizer Inc
Novartis AG
Sanofi
Merck & Co Inc
Aspan Holdings
China Shineway Pharmaceutical Group Limited
Boston Scientific Corporation
Ipsen Pharma
Revance therapeutics Inc
Merz Pharma

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.